Business
Upcoming Presentation
Upcoming Presentation.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 2891E Physiomics PLC 05 April 2011 \n \n\n \nPhysiomics plc\n(\"Physiomics\" or \"the Company\")\n \nPhysiomics to present on Lilly Collaboration at the Annual Meeting for American Association for Cancer Research (\"AACR\") \n \nPhysiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR 102nd Annual Meeting 2011, taking place in the Orange County Convention Center, Orlando, Florida on 2-6 April 2011. \n \nDr Eric Fernandez, Project Leader at Physiomics, will present on a validation of our Virtual Tumour platform, which was completed in collaboration with Eli Lilly and Company ('Lilly') the global biopharmaceutical company.\n \nIn this validation study, Physiomics' Virtual Tumour model accurately predicted tumour growth in a pre-clinical model for two anti-cancer drug combinations, using experimental data collected from single drug exposures. This test was conducted in a single-blind manner, the experimental results of the combinations being revealed to Physiomics only after Physiomics had provided the Virtual Tumour simulation results to Lilly.\n \nThe Virtual Tumour platform is used to design optimal combination chemotherapy regimens. Thousands of simulations can be performed in silico if necessary to find the best treatment regime and save biopharmaceutical customers like Lilly time and money.\n \nThe abstract (\"Predicting the effect of combination schedules on xenograft tumor using the Virtual Tumor\", No 4918) will be published in the 2011 Proceedings of the AACR and will be presented in the \"Integrative Genomic Biology\" poster session, scheduled 08:00 AM - 12:00 PM, 6 April 2011.\n \nMore information about the conference may be found at:\nhttp://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx\n \nDr Mark Chadwick, CEO of Physiomics, said\n \n\"We are particularly pleased to present these results at this year's AACR annual meeting. We believe this blind validation approach will attract further large pharma customers.\"\n \nEnquiries:\n \nPhysiomics plc &nbs...